Action is needed to improve endometriosis diagnosis and care

Start off 2024 with a thought-provoking article addressing the pressing challenges in endometriosis care and research. Authored by Linda Giudice, Andrew Horne and Stacey Missmer, this piece highlights the need for increased investment, interdisciplinary collaboration, and enhanced awareness. The narrow perception of endometriosis as solely a gynecologic disorder underscores the importance of broader, multidisciplinary approaches to diagnosis and treatment. The article discusses key issues inhibiting timely diagnosis and treatment, including the complex nature of the disorder and underfunding in research. This insightful commentary in the December 2023 issue of Nature Communications provides a comprehensive understanding of the issues and proposed solutions.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.